Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD27ζ CAR-T cells
- Development stage
- Preclinical
- Lead developer
- CHUV
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CD27ζ CAR-T cells are an experimental chimeric antigen receptor (CAR) T-cell therapy designed to target CD70, a member of the tumor necrosis factor (TNF) superfamily that is overexpressed in various cancers, including acute myeloid leukemia (AML), renal cell carcinoma, and certain lymphomas. Unlike most CAR-T therapies that use antibody-derived single-chain variable fragments (scFvs) for antigen recognition, CD27ζ CARs utilize the natural ligand of CD70, which is CD27, as the extracellular binding domain. The signaling component consists of the CD3ζ (zeta) endodomain. Research presented at ASH 2024 by the University of Lausanne and CHUV highlights the development of optimized CD27-based CARs, such as the CD8αH-CD27ζ variant, which incorporates a CD8α hinge and a CD27 transmembrane domain to enhance anti-leukemic potency and cytokine production in preclinical models.
- Other names
- CD27-zeta CAR-T cellsCD-27-zeta CAR-T cellsCD 27-zeta CAR-T cellsCD27-CD3z CAR-T cellsCD-27-CD3z CAR-T cellsCD 27-CD3z CAR-T cellsCD70-targeted CAR-T cellsCD-70-targeted CAR-T cellsCD 70-targeted CAR-T cells
02
Targets
CD70 (Cluster of Differentiation 70)
Beyond the preview
Go deeper on CD27ζ CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD27ζ CAR-T cells.